Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Lipid Regulating Agents

All Drugs and Chemicals

Atorvastatin

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Enzyme Inhibitors

Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.

Carsten Rose, MD

The purpose of this study is to monitor:

* Tumor biological alterations following two weeks of neo-adjuvant statin therapy.
* Effects of statins on tumor proliferation.
* Functional studies on the mevalonate pathway.

Blood samples and three core biopsies are taken after diagnosis. Treatment with atorvastatin at a daily dosis of 80 mg is initiated 14 days before planned surgery. Translational research will be performed from the core biopsy and blood samples taken before surgery and from the specimen from surgery.

Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer

A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer: A Window-of-Opportunity Study

Lund University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer	NCT00816244	Breast Cancer Postmenopausal	Atorvastatin	18 Years -	Lund University Hospital
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer	NCT00816244	Breast Cancer Postmenopausal	Atorvastatin	18 Years -	Lund University Hospital

Spots Global Cancer Trial Database for cell cycle regulators